# Regenerex Pharma, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Regenerex Pharma, Inc.). ## Overview Regenerex Pharma, Inc. is a U.S.-based pharmaceutical preparations company focused on advanced wound care healing products. Its business centers on proprietary wound-closure technologies, including QBx™, for chronic, acute, and contamination-controlled wound treatment across medical care settings. ## Products & services • Chronic wound closure technology • Acute wound acceleration technology • Contamination control technology • QBx™ wound-healing active ingredient • Wound Closure System protocols • AI-driven wound management information system - **Advanced wound care technologies** (45%) — Proprietary technologies and formulations for chronic, acute, and contaminated wounds. - **Wound Closure System protocols** (20%) — Clinical protocols and treatment pathways used with the company's wound products. - **QBx™ active ingredient platform** (20%) — Core biologic ingredient designed to down-regulate proteases and support healing. - **Digital wound management tools** (10%) — AI-enabled patient tracking and medication support software for wound care programs. - **Distribution and commercialization services** (5%) — Partner-led commercialization, distributor development, and market access support. - Chronic wound closure technology - Acute wound acceleration technology - Contamination control technology - QBx™ wound-healing active ingredient - Wound Closure System protocols - AI-driven wound management information system ## Customers Regenerex sells into healthcare payors and care-delivery organizations that manage chronic and acute wounds, especially where reimbursement and outcomes are tightly linked. Its target buyers include Medicaid programs, government-funded home care providers, veterans and correctional healthcare systems, private insurance networks, and wound care providers that need products and protocols to improve closure rates and reduce total treatment cost. - **State Medicaid programs** (primary) — Buy wound care products and protocols to manage high-cost chronic wound populations at lower total cost. - **Home health and nursing homes** (primary) — Use wound closure products for aging patients with diabetic, pressure, and venous ulcers. - **Private insurance networks** (secondary) — Seek preferred-provider arrangements and reimbursable wound care solutions that improve outcomes. - **Government healthcare systems** (secondary) — Includes VA and correctional facilities that need standardized wound protocols and cost control. - **International distributors** (emerging) — Purchase or distribute the company's products in Asia and the Middle East. - State Medicaid programs seeking lower-cost wound management - Government-funded home care providers treating chronic wounds - Private insurance networks looking for preferred-provider access - Veterans Administration and correctional healthcare systems - Home health, nursing homes, and wound care clinics - International distributors serving regional healthcare systems ## Geography Regenerex is headquartered in Tennessee and also maintains an office in Nevada, with operations organized around U.S. commercialization and outsourced manufacturing. The company is pursuing distribution and managed-care opportunities in southeastern U.S. states, Puerto Rico, Asia, and the Middle East, so its growth depends on both domestic reimbursement access and international distributor relationships. - **United States** (80%) — Primary commercialization, reimbursement, and care-provider market. - **Asia and Middle East** (20%) — Target international distributor markets; no disclosed revenue split. - Headquartered in Gordonsville, Tennessee - Identity office in Las Vegas, Nevada - U.S. Southeast is a key target for Medicaid contracts - Puerto Rico is discussed for federally funded programs - Asia and the Middle East are target export markets - Manufacturing and distribution are largely outsourced ## Strategy Regenerex is focused on converting its wound-care technologies into reimbursable contracts with state Medicaid programs, government-funded providers, and private networks. It is also building international distributor relationships and adding digital wound-management capabilities to broaden its offering beyond a product-only model. - **Win reimbursement-backed U.S. contracts** (short-term) — The business depends on payor access and contracted patient volume to commercialize wound products. - **Build international distribution** (medium-term) — Distributor-led expansion can extend the addressable market without heavy owned infrastructure. - **Differentiate through technology and data** (medium-term) — Clinical protocols and AI tools can support adoption, adherence, and reimbursement value. - Secure Medicaid and managed-care agreements in southeastern states - Expand access through private insurance preferred-provider status - Develop distributor relationships in Asia and the Middle East - Use AI-enabled wound tracking to strengthen clinical differentiation - Support commercialization with outsourced manufacturing and leasing - Broaden revenue sources across public and private healthcare channels ## Risks Regenerex is a development-stage healthcare company with no established revenue base, so execution depends on winning contracts, obtaining reimbursement access, and raising capital. Its business is also exposed to regulatory, clinical, and commercialization risk because wound-care products must prove efficacy, fit payor economics, and compete against established providers. - **Going-concern and financing risk** [critical] — The company needs external capital to fund operations and commercialization before meaningful revenue is established. - **Reimbursement and payor access risk** [high] — The business model relies on Medicaid, Medicare, and insurer coverage for wound-care adoption. - **Commercialization and adoption risk** [high] — Healthcare buyers may be slow to adopt new wound-care protocols without strong clinical and economic proof. - **Competition risk** [medium] — The company competes with established wound-care and consumer product companies with scale and distribution. - **Cybersecurity and cash theft risk** [high] — A reported bank-account hacking incident shows exposure to fraud and treasury controls. - No revenue history increases dependence on financing and contract wins - Reimbursement access is critical because buyers are payor-driven - Clinical adoption risk if products do not outperform alternatives - Competition from established wound-care and consumer health companies - International expansion adds distributor and regulatory execution risk - Asset-light model can create supply and quality-control dependence ## Accounting The most important accounting issues are valuation of stock-based compensation and warrants, fair value measurement of issued securities, and accounting for acquired intellectual property. Because the company has limited operating history and no revenue, investors should also watch going-concern disclosures, lease commitments, and any impairment or recoverability questions tied to capitalized technology assets. - **Stock-based compensation and warrants** — Expense recognition and equity dilution - **Purchased intellectual property** — Balance sheet carrying value and amortization - **Going-concern assessment** — Disclosure and investor risk assessment - **Lease accounting** — Right-of-use assets and lease liabilities - Stock-based compensation and warrant valuation use Black-Scholes assumptions - Purchased technology and IP require judgment on useful life and recoverability - Going-concern disclosure reflects dependence on future financing - Lease accounting matters because facilities and equipment are leased - No revenue means expense recognition and capitalization choices drive results --- *Last updated: 2026-04-29T04:51:32.670152+00:00*